lacosamide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 59 Diseases   24 Trials   24 Trials   1999 News 


«12...1213141516171819202122...2526»
  • ||||||||||  lithium / Generic mfg., ibuprofen / Generic mfg., quetiapine / Generic mfg.
    [VIRTUAL] CRITICAL CARE COMPLICATIONS OF LITHIUM TOXICITY () -  Oct 12, 2020 - Abstract #CHEST2020CHEST_2755;    
    Here, we discuss the critical care management of two cases of lithium toxicity-associated seizures.CASE PRESENTATION: Case 1:A 54-year-old female with schizophrenia on lithium and quetiapine recently initiated on a course of ibuprofen for sciatica presented with nausea, vomiting, diarrhea, and altered sensorium...Her metabolic encephalopathy slowly improved, with eventual transfer to the psychiatric ward for further medication titration.Case 2:A 67-year-old female with bipolar disorder on lithium and haloperidol recently discharged after titration of medications in the psychiatric ward presented with altered sensorium...The trachea was intubated and anti-epileptics were initiated including a midazolam drip, levetiracetam load, lacosamide, and fosphenytoin... Lithium is a high-risk medication necessitating regular monitoring, with potential severe neurotoxicity.
  • ||||||||||  Vimpat (lacosamide) / UCB, Daiichi Sankyo
    Journal:  Preparation of Acute Human Hippocampal Slices for Electrophysiological Recordings. (Pubmed Central) -  Oct 8, 2020   
    This activity is sensitive to established AED lacosamide or novel antiepileptic candidates, such as dimethylethanolamine (DMEA)...Furthermore, mechanisms of action postulated for specific compounds can be validated using this approach in human tissue (e.g., using patch-clamp recordings). To conclude, investigation of vital human brain tissue ex vivo (here, resected hippocampus from patients suffering from temporal lobe epilepsy) will improve the current knowledge of physiological and pathological mechanisms in the human brain.
  • ||||||||||  Vimpat (lacosamide) / UCB, Daiichi Sankyo, levetiracetam / Generic mfg.
    [VIRTUAL] A Case Report of Mesial Temporal Lobe Epilepsy Misdiagnosed as Cyclic Vomiting Syndrome () -  Sep 30, 2020 - Abstract #ANA2020ANA_497;    
    The aforementioned patient was diagnosed with cyclic vomiting syndrome due to stereotypical episodes of vomiting and marijuana use. It is imperative to include epileptic seizures on the list of possible diagnoses in patients with otherwise unexplained nausea and vomiting to allow for earlier diagnosis and treatment.
  • ||||||||||  Fycompa (perampanel) / Eisai
    [VIRTUAL] Late Perampanel Treatment Stops Severe Midazolam-Refractory Status Epilepticus () -  Sep 30, 2020 - Abstract #ANA2020ANA_486;    
    Perampanel is potent in stopping midazolam- refractory SE even when given 60 min following SE onset. Used as a late second-line treatment, perampanel is more effective in terminating SE than valproate, levetiracetam, fosphenytoin or lacosamide in this animal model of severe benzodiazepine-refractory SE.
  • ||||||||||  lacosamide / Generic mfg., levetiracetam / Generic mfg.
    Enrollment open:  Seizure Prophylaxis in Patients With Glioma or Brain Metastasis (clinicaltrials.gov) -  Sep 30, 2020   
    P2,  N=232, Recruiting, 
    Shortening the titration interval with appropriate target dosage may be feasible in appropriate clinical situations. Suspended --> Recruiting
  • ||||||||||  Vimpat (lacosamide) / UCB, Daiichi Sankyo
    Preclinical, Journal:  Targeted delivery of lacosamide-conjugated gold nanoparticles into the brain in temporal lobe epilepsy in rats. (Pubmed Central) -  Sep 20, 2020   
    Ultrastructurally, LCM-GNPs were observed in the brain parenchyma after intravenous injection to animals with TLE. We conclude that glucose-coated GNPs can be efficient in transferring effective doses of LCM into the brain enabling elimination of the need to administer high doses of the drug, and hence, may represent a new approach in the treatment of drug-resistant TLE.
  • ||||||||||  Vimpat (lacosamide) / UCB, Daiichi Sankyo
    Clinical, PK/PD data, Journal:  Safety, tolerability, and pharmacokinetics of weight-based IV loading dose of lacosamide in the ICU. (Pubmed Central) -  Sep 20, 2020   
    Data collected were age, total body weight, body mass index (BMI), loading dose, post-IV infusion LCM blood level, duration of infusion, blood pressure, heart rate, oxygen saturation, mean arterial pressures, and documented initiation of pressor agents during or within in 30 min of infusion. Larger doses >8 mg/kg of IV LCM that can be safely administered in ICU patients produce effective plasma levels of 15-20 μg/ml with relatively constant volume of distribution.
  • ||||||||||  Journal:  Timing use of novel anti-epileptic drugs: is earlier better? (Pubmed Central) -  Sep 17, 2020   
    For this reason, the third-generation AEDs may be used earlier and earlier in epileptic patients. Further head-to-head comparisons are needed to determine the exact position of third-generation AEDs relative to conventional AEDs.
  • ||||||||||  Vimpat (lacosamide) / UCB, Daiichi Sankyo, levetiracetam / Generic mfg.
    Clinical, Journal:  Effects of levetiracetam and lacosamide on therapeutic efficacy and neural function in patients with epilepsy. (Pubmed Central) -  Sep 10, 2020   
    The combination therapy greatly increased the quality of life score and the 1-year drug retention rate. To sum up, levetiracetam tablets combined with LCM significantly enhanced the therapeutic effect and improved the neural function in patients with refractory partial seizures, however this therapy may cause a slight adverse effect on BMD and bone metabolism in the short term.
  • ||||||||||  Vimpat (lacosamide) / UCB, Daiichi Sankyo, carbamazepine / Generic mfg.
    Clinical, Journal:  Lacosamide in patients with epilepsy of cerebrovascular etiology. (Pubmed Central) -  Sep 1, 2020   
    P=N/A, P3
    To sum up, levetiracetam tablets combined with LCM significantly enhanced the therapeutic effect and improved the neural function in patients with refractory partial seizures, however this therapy may cause a slight adverse effect on BMD and bone metabolism in the short term. These exploratory post hoc analyses suggested lacosamide was generally well tolerated and effective in patients with CVEE, with data from the initial monotherapy trial suggesting numerically better efficacy than carbamazepine-CR.
  • ||||||||||  Trial completion, Enrollment change:  PADRE: Pharmacokinetics of Antiepileptics in Patients on CRRT (clinicaltrials.gov) -  Aug 31, 2020   
    P4,  N=18, Completed, 
    These exploratory post hoc analyses suggested lacosamide was generally well tolerated and effective in patients with CVEE, with data from the initial monotherapy trial suggesting numerically better efficacy than carbamazepine-CR. Recruiting --> Completed | N=30 --> 18
  • ||||||||||  pregabalin / Generic mfg.
    Review, Journal:  Epilepsy and breastfeeding: from myth to reality (Pubmed Central) -  Aug 23, 2020   
    Lamotrigine, phenobarbital, pregabalin, primidone, tiagabine, eslicarbazepine, brivaracetam, perampanel, zonisamide, lacosamide or the sporadic use of benzodiazepines in low doses are considered quite safe, with a low risk for breastfeeding. The other AEDs present a very low risk for breastfeeding.
  • ||||||||||  Journal:  Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee. (Pubmed Central) -  Aug 22, 2020   
    A structured literature search (MEDLINE, Embase, CENTRAL, CINAHL) was performed to identify original studies on the treatment of CRSE in children and adults using IV brivaracetam, ketamine, lacosamide, levetiracetam (LEV), midazolam (MDZ), pentobarbital (PTB; and thiopental), propofol (PRO), and valproic acid (VPA)...For the treatment of established convulsive SE (ie, not RSE), LEV, VPA, and fosphenytoin are likely equally effective, but whether this is also true for CRSE is unknown. Triple-masked, randomized controlled trials are needed to compare the effectiveness of parenteral anesthetizing and nonanesthetizing ASMs in the treatment of CRSE.
  • ||||||||||  Vimpat (lacosamide) / UCB, Daiichi Sankyo, Ocrevus (ocrelizumab) / Roche, Biogen
    [VIRTUAL] Multiple Sclerosis, variant Marburg, an uncommon form: about a case. () -  Aug 16, 2020 - Abstract #MSDC2020MSDC_338;    
    Following diagnosis, steroid boluses have been prescribed and treatment with Ocrelizumab (positive anti-JC Acs) will begin.Conclusions The clinical course of the Marburg variant is unpredictable, sometimes with poor clinical-radiological correlation as indicated in the literature. It is very important to take it into account in the differential diagnosis of demyelinating diseases and of these with swelling-like neoplastic lesions for their adequate follow-up and early treatment.